The FirstTake Podcast – Two US biotechs run into trouble at the FDA

On this week’s episode FirstWord editors Simon King, Michael Flanagan and Becky Simon delve into the potential implications of FibroGen’s newly disclosed safety data for the investigational anaemia drug roxadustat ahead of an FDA advisory committee meeting, catch up with drug safety expert Anthony Cox to discuss the latest pharmacovigalence developments concerning AstraZeneca’s COVID-19 vaccine in Europe and take a closer look at Acadia Pharmaceuticals’ efforts to expand approval of the drug Nuplazid to treat dementia related psychosis.

Listen here 

To read more ViewPoints articles, click here.